Banner - NPPA Connect
Logo Image
|Articles|August 1, 2003

Biochemotherapy Gets Thumb's Down

Chicago - The promise of biochemotherapy for stage IV malignant melanoma has not held up to scrutiny, and the value of this form of treatment seems nil, according to recent discouraging findings from major phase III clinical trials.

Related Content

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care
Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

View more
Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes
Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

View more